A detailed history of Israel Englander (Millennium Management LLC) transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Millennium Management LLC holds 242,212 shares of ABUS stock, worth $755,701. This represents 0.0% of its overall portfolio holdings.

Number of Shares
242,212
Previous 1,537,924 84.25%
Holding current value
$755,701
Previous $3.84 Million 83.77%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.26 - $2.92 $2.93 Million - $3.78 Million
-1,295,712 Reduced 84.25%
242,212 $624,000
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $277,596 - $417,215
-164,258 Reduced 9.65%
1,537,924 $3.84 Million
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $93,219 - $127,344
41,616 Added 2.51%
1,702,182 $3.92 Million
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $428,492 - $595,661
-192,149 Reduced 10.37%
1,660,566 $5.03 Million
Q4 2022

Feb 14, 2023

SELL
$1.91 - $2.85 $3.17 Million - $4.72 Million
-1,657,473 Reduced 47.22%
1,852,715 $4.32 Million
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $1.22 Million - $1.87 Million
-648,876 Reduced 15.6%
3,510,188 $6.7 Million
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $4.24 Million - $6.79 Million
2,142,740 Added 106.27%
4,159,064 $11.3 Million
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $2.48 Million - $4.07 Million
-1,022,861 Reduced 33.66%
2,016,324 $6.01 Million
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $6.27 Million - $9.3 Million
2,017,490 Added 197.46%
3,039,185 $11.8 Million
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $2.71 Million - $4.72 Million
1,021,695 New
1,021,695 $4.38 Million
Q2 2021

Aug 16, 2021

SELL
$2.5 - $3.51 $1.31 Million - $1.84 Million
-523,263 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$3.14 - $4.84 $1.07 Million - $1.66 Million
342,301 Added 189.16%
523,263 $1.74 Million
Q4 2020

Feb 16, 2021

BUY
$2.76 - $4.97 $499,455 - $899,381
180,962 New
180,962 $642,000
Q3 2020

Nov 16, 2020

SELL
$1.75 - $6.2 $389,502 - $1.38 Million
-222,573 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$0.91 - $2.36 $568,377 - $1.47 Million
-624,591 Reduced 73.73%
222,573 $405,000
Q1 2020

May 14, 2020

BUY
$1.01 - $3.42 $556,699 - $1.89 Million
551,188 Added 186.23%
847,164 $856,000
Q4 2019

Feb 14, 2020

SELL
$0.87 - $2.89 $52,278 - $173,660
-60,090 Reduced 16.88%
295,976 $823,000
Q3 2019

Nov 14, 2019

SELL
$1.34 - $2.4 $221,045 - $395,901
-164,959 Reduced 31.66%
356,066 $543,000
Q2 2019

Aug 15, 2019

BUY
$1.46 - $4.44 $463,802 - $1.41 Million
317,673 Added 156.22%
521,025 $1.08 Million
Q2 2019

Aug 14, 2019

BUY
$1.46 - $4.44 $296,893 - $902,882
203,352 New
203,352 $415,000
Q4 2018

Feb 14, 2019

SELL
$3.5 - $9.66 $108,234 - $298,725
-30,924 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$7.85 - $12.35 $440,895 - $693,637
-56,165 Reduced 64.49%
30,924 $292,000
Q2 2018

Aug 14, 2018

BUY
$5.0 - $7.35 $369,410 - $543,032
73,882 Added 559.42%
87,089 $636,000
Q1 2018

May 15, 2018

SELL
$4.4 - $6.05 $302,720 - $416,240
-68,800 Reduced 83.9%
13,207 $66,000
Q4 2017

Feb 14, 2018

BUY
$4.45 - $7.7 $275,726 - $477,099
61,961 Added 309.09%
82,007 $414,000
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $68,156 - $140,322
20,046
20,046 $124,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $468M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.